CLSD Quote, Financials, Valuation and Earnings

Perspective Therapeutics has a net margin of -740.66% compared to Clearside Biomedical's net margin of --. Clearside Biomedical's return on equity of -- beat Perspective Therapeutics's return on equity of --.

Clearside Biomedical has a consensus price target of --, signalling upside risk potential of 587.84%. On the other hand Perspective Therapeutics has an analysts' consensus of -- which suggests that it could grow by 466.67%. Given that Clearside Biomedical has higher upside potential than Perspective Therapeutics, analysts believe Clearside Biomedical is more attractive than Perspective Therapeutics.

Clearside Biomedical has a beta of 2.292, which suggesting that the stock is 129.225% more volatile than S&P 500. In comparison Perspective Therapeutics has a beta of 1.129, suggesting its more volatile than the S&P 500 by 12.894%.

Clearside Biomedical has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Perspective Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Clearside Biomedical pays -- of its earnings as a dividend. Perspective Therapeutics pays out -- of its earnings as a dividend.

Clearside Biomedical quarterly revenues are $1M, which are larger than Perspective Therapeutics quarterly revenues of --. Clearside Biomedical's net income of -$7.7M is higher than Perspective Therapeutics's net income of -$15.1M. Notably, Clearside Biomedical's price-to-earnings ratio is -- while Perspective Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Clearside Biomedical is 7.98x versus 15.39x for Perspective Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Crinetics Pharmaceuticals has a net margin of -740.66% compared to Clearside Biomedical's net margin of -18560.15%. Clearside Biomedical's return on equity of -- beat Crinetics Pharmaceuticals's return on equity of -42.43%.

Clearside Biomedical has a consensus price target of --, signalling upside risk potential of 587.84%. On the other hand Crinetics Pharmaceuticals has an analysts' consensus of $75.07 which suggests that it could grow by 40.32%. Given that Clearside Biomedical has higher upside potential than Crinetics Pharmaceuticals, analysts believe Clearside Biomedical is more attractive than Crinetics Pharmaceuticals.

Clearside Biomedical has a beta of 2.292, which suggesting that the stock is 129.225% more volatile than S&P 500. In comparison Crinetics Pharmaceuticals has a beta of 0.597, suggesting its less volatile than the S&P 500 by 40.297%.

Clearside Biomedical has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Crinetics Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Clearside Biomedical pays -- of its earnings as a dividend. Crinetics Pharmaceuticals pays out -- of its earnings as a dividend.

Clearside Biomedical quarterly revenues are $1M, which are larger than Crinetics Pharmaceuticals quarterly revenues of $399K. Clearside Biomedical's net income of -$7.7M is higher than Crinetics Pharmaceuticals's net income of -$76.8M. Notably, Clearside Biomedical's price-to-earnings ratio is -- while Crinetics Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Clearside Biomedical is 7.98x versus -- for Crinetics Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Corvus Pharmaceuticals has a net margin of -740.66% compared to Clearside Biomedical's net margin of --. Clearside Biomedical's return on equity of -- beat Corvus Pharmaceuticals's return on equity of --.

Clearside Biomedical has a consensus price target of --, signalling upside risk potential of 587.84%. On the other hand Corvus Pharmaceuticals has an analysts' consensus of $15.75 which suggests that it could grow by 215%. Given that Clearside Biomedical has higher upside potential than Corvus Pharmaceuticals, analysts believe Clearside Biomedical is more attractive than Corvus Pharmaceuticals.

Clearside Biomedical has a beta of 2.292, which suggesting that the stock is 129.225% more volatile than S&P 500. In comparison Corvus Pharmaceuticals has a beta of 1.049, suggesting its more volatile than the S&P 500 by 4.936%.

Clearside Biomedical has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Corvus Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Clearside Biomedical pays -- of its earnings as a dividend. Corvus Pharmaceuticals pays out -- of its earnings as a dividend.

Clearside Biomedical quarterly revenues are $1M, which are larger than Corvus Pharmaceuticals quarterly revenues of --. Clearside Biomedical's net income of -$7.7M is higher than Corvus Pharmaceuticals's net income of -$40.2M. Notably, Clearside Biomedical's price-to-earnings ratio is -- while Corvus Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Clearside Biomedical is 7.98x versus -- for Corvus Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Viking Therapeutics has a net margin of -740.66% compared to Clearside Biomedical's net margin of --. Clearside Biomedical's return on equity of -- beat Viking Therapeutics's return on equity of --.

Clearside Biomedical has a consensus price target of --, signalling upside risk potential of 587.84%. On the other hand Viking Therapeutics has an analysts' consensus of $110.00 which suggests that it could grow by 160.36%. Given that Clearside Biomedical has higher upside potential than Viking Therapeutics, analysts believe Clearside Biomedical is more attractive than Viking Therapeutics.

Clearside Biomedical has a beta of 2.292, which suggesting that the stock is 129.225% more volatile than S&P 500. In comparison Viking Therapeutics has a beta of 0.884, suggesting its less volatile than the S&P 500 by 11.566%.

Clearside Biomedical has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Viking Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Clearside Biomedical pays -- of its earnings as a dividend. Viking Therapeutics pays out -- of its earnings as a dividend.

Clearside Biomedical quarterly revenues are $1M, which are larger than Viking Therapeutics quarterly revenues of --. Clearside Biomedical's net income of -$7.7M is higher than Viking Therapeutics's net income of -$24.9M. Notably, Clearside Biomedical's price-to-earnings ratio is -- while Viking Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Clearside Biomedical is 7.98x versus -- for Viking Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.